LCD L39007: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer — Noridian
Policy LCD-L39007 · Oncology
New LCD for prostate cancer risk-stratification impacts billing.
Code intelligence
0403U reimbursement alerts
Policy changes, MAC LCD updates, and CMS guidance matched to code 0403U.
Elevated code risk
Signal breakdown
7 shown · 7 total in platform
Risk: Elevated
0
Critical
0%
7
High
100%
0
Routine
0%
0
Low
0%
New this month
—
alerts added in last 30 days
Effective soon
—
no upcoming deadlines
High
LCD L38985: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer — Palmetto GBA
Policy LCD-L38985 · Oncology
New MolDX requires billing team review.
LCD L39005: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer — Noridian
Policy LCD-L39005 · Oncology
New LCD for prostate cancer biomarkers impacts billing strategies.
LCD L36021: MolDX: Molecular Diagnostic Tests (MDT) — CGS
Policy LCD-L36021 · Clinical Laboratory
New MolDX policy effective in 2025 may alter billing processes.
LCD L36256: MolDX: Molecular Diagnostic Tests (MDT) — Noridian
Policy LCD-L36256 · Clinical Laboratory
New molecular diagnostics policy may impact billing processes.
LCD L38997: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer — CGS
Policy LCD-L38997 · Urology
New LCD for prostate cancer biomarkers impacts billing.
LCD L35160: MolDX: Molecular Diagnostic Tests (MDT) — Noridian
Policy LCD-L35160 · Clinical Laboratory
New MolDX guidelines may alter MDT billing processes.
Audit documentation
Building an audit file that includes 0403U?
The Tripwire Audit Pack exports 12 months of Oncology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.
Get the Oncology audit pack — $349One-time purchase · not a subscription